Revela has closed a £411,000 pre-seed funding round. The round was backed by PXN Ventures North of England through their PraeSeed programme, with participation from angel investors from Sixth Wave Ventures, Mint Ventures, Alma Angels, and Leeds Angels.
Revela is developing software that performs enhanced analysis of ultrasound scans to identify signs of endometriosis. The software automatically analyzes images taken early in the diagnostic pathway and returns a report to clinicians highlighting signs of endometriosis for clinical review. The technology aims to reduce the delay between first presentation to a GP and diagnosis then treatment planning.
Current endometriosis diagnosis methods rely on invasive surgery, which can take years. Revela’s machine learning algorithms use carefully curated, high-quality data to help identify subtle signs of endometriosis from ultrasound images.
“At Sixth Wave Ventures, we invest in and support truly pioneering startups and the exceptional founders behind them through our Sixth Wave angel group,” said Steve Kelly, co-founder and partner at Sixth Wave Ventures. “Revela is a fantastic example — a company tackling a major global women’s health challenge with innovation, scientific rigor, and real-world impact.”
“At Mint Ventures we back women led purpose driven companies who are building products the world has been missing,” said Mint Ventures. “We believe Revela is poised to make a significant difference to women’s health, and we’re excited to be part of their journey.”
The funding will be used to access larger training datasets and grow the team to accelerate progress toward the first product. The company is building its technology with patients and clinicians.
Endometriosis affects millions of women globally.
